AUS
NZ
UK
CA
USA
IND
Highlights
Abingdon Health has partnered with Okos Diagnostics to co-develop a lateral flow test for avian flu.
The collaboration aims to adapt Okos' prototype for use in both animal and human health applications.
The deal includes manufacturing and commercialisation aspects, bringing innovative diagnostic technology to the global market.
Abingdon Health, a company listed under the FTSE350, has entered a strategic partnership with Okos Diagnostics B.V., a Netherlands-based diagnostic firm specialising in lateral flow technologies. This partnership, aimed at developing a lateral flow test for avian flu, aligns with Abingdon Health's commitment to advancing diagnostic solutions within both the animal and human health sectors.
Collaboration Details
The new collaboration focuses on adapting Okos’ prototype lateral flow test for avian flu, with an emphasis on applications in both human and animal health. The partnership covers co-development, manufacturing, and commercialisation of the test, signalling Abingdon Health's ongoing efforts to expand its diagnostic portfolio.
Abingdon Health and Okos Diagnostics will work together to refine the prototype, ensuring it meets the standards required for widespread application. This partnership is part of Abingdon Health's strategy to enhance its presence in the global diagnostic market, especially in areas where rapid detection is crucial.
Advancing Lateral Flow Technology
Lateral flow tests are commonly used for detecting various pathogens and infections due to their ease of use and fast results. By partnering with Okos Diagnostics, Abingdon Health aims to leverage this technology to address the growing need for efficient testing solutions, particularly in the context of avian flu outbreaks. The development of a robust and reliable test could play a key role in controlling the spread of the disease, providing an effective tool for both health professionals and the general public.
Strategic Partnership
Dr Chris Hand, executive chairman of Abingdon Health, expressed enthusiasm regarding the collaboration, emphasising the potential to bring these innovative tests to the global market. The agreement between the two companies outlines a shared commitment to developing high-quality diagnostic tools that meet international standards, further solidifying Abingdon Health's position in the diagnostic sector.
The partnership also highlights the importance of cross-border collaboration in addressing global health challenges. Okos Diagnostics, with its expertise in lateral flow technologies, complements Abingdon Health’s established track record in developing diagnostic products for a variety of health-related concerns.
Abingdon Health's latest move reflects its proactive approach to addressing emerging health concerns with effective diagnostic solutions. This partnership underscores the importance of innovation in the healthcare sector and the potential for diagnostic technologies to address public health issues swiftly and accurately.
